Center for Primary Health Care Research, Lund University/Region Skåne, Malmö, 20502, Sweden.
Department of Family Medicine and Community Health, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Nat Commun. 2018 Jun 18;9(1):2367. doi: 10.1038/s41467-018-04814-4.
Recent evidence suggests that cholera toxin might have multiple functions regarding the ability to regulate the immune system. However, it is unknown whether subsequent administration of cholera vaccine might affect the mortality rate in patients with prostate cancer. Here we report that patients in Sweden, who were diagnosed with prostate cancer between July 2005 and December 2014 and used cholera vaccine, have a decreased risk of death from prostate cancer (HR, 0.57; 95% CI, 0.40-0.82) as compared to patients with prostate cancer but without cholera vaccine use, adjusted for a range of confounding factors. In addition, patients using cholera vaccine show a decreased risk of death overall (HR, 0.53; 95% CI, 0.41-0.69). The decreased mortality rate is largely consistent, irrespective of patients' age or tumor stage at diagnosis. In this population-based study, we suggest that subsequent administration of cholera vaccine after prostate cancer diagnosis might reduce the mortality rate.
最近的证据表明，霍乱毒素可能具有多种调节免疫系统的功能。然而，目前尚不清楚随后接种霍乱疫苗是否会影响前列腺癌患者的死亡率。在这里，我们报告称，在 2005 年 7 月至 2014 年 12 月期间被诊断患有前列腺癌的瑞典患者，如果使用霍乱疫苗，其死于前列腺癌的风险降低（HR，0.57；95%CI，0.40-0.82），与未使用霍乱疫苗的前列腺癌患者相比，调整了一系列混杂因素。此外，使用霍乱疫苗的患者总体死亡风险降低（HR，0.53；95%CI，0.41-0.69）。无论患者的年龄或诊断时的肿瘤分期如何，死亡率的降低基本一致。在这项基于人群的研究中，我们建议在前列腺癌诊断后随后接种霍乱疫苗可能会降低死亡率。
